{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:42:35Z","timestamp":1794534155501,"version":"4.9.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CSIR NET Senior Research Fellowship","award":["09\/0070(13660)\/2022-EMR-I"],"award-info":[{"award-number":["09\/0070(13660)\/2022-EMR-I"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-10589-8","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:12:45Z","timestamp":1759749165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["In silico identification of prospective p53-MDM2 inhibitors from ASINEX database using a comprehensive molecular modelling approach"],"prefix":"10.1038","volume":"15","author":[{"given":"Dushyant D.","family":"Kotadiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmesh A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"10589_CR1","unstructured":"Society American Cancer. Global cancer facts and figures. American Cancer Society 1\u201348 at. (2024)."},{"key":"10589_CR2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4103\/ijmr.ijmr_1821_22","volume":"156","author":"K Sathishkumar","year":"2022","unstructured":"Sathishkumar, K., Chaturvedi, M., Das, P., Stephen, S. & Mathur, P. Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer registry programme, India. Indian J. Med. Res. 156, 598 (2022).","journal-title":"Indian J. Med. Res."},{"key":"10589_CR3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2174\/09298665113209990056","volume":"21","author":"G Sowmya","year":"2013","unstructured":"Sowmya, G. & Ranganathan, S. Protein-Protein interactions and prediction: A comprehensive overview. Protein Pept. Lett. 21, 779\u2013789 (2013).","journal-title":"Protein Pept. Lett."},{"key":"10589_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","volume":"408","author":"B Vogelstein","year":"2000","unstructured":"Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307\u2013310 (2000).","journal-title":"Nature"},{"key":"10589_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nrc2012","volume":"6","author":"F Toledo","year":"2006","unstructured":"Toledo, F. & Wahl, G. M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer. 6, 909\u2013923 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"10589_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrm2147","volume":"8","author":"KH Vousden","year":"2007","unstructured":"Vousden, K. H. & Lane, D. P. p53 in health and disease. Nat. Rev. Mol. Cell. Biol. 8, 275\u2013283 (2007).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10589_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/cancers10060189","volume":"10","author":"DE Moulder","year":"2018","unstructured":"Moulder, D. E., Hatoum, D., Tay, E., Lin, Y. & McGowan, E. M. The roles of p53 in mitochondrial dynamics and cancer? metabolism: the pendulum between survival and death in breast cancer?? Cancers (Basel). 10, 189 (2018).","journal-title":"Cancers (Basel)"},{"key":"10589_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","volume":"85","author":"AC Joerger","year":"2016","unstructured":"Joerger, A. C. & Fersht, A. R. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu. Rev. Biochem. 85, 375\u2013404 (2016).","journal-title":"Annu. Rev. Biochem."},{"key":"10589_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","volume":"15","author":"K Sabapathy","year":"2018","unstructured":"Sabapathy, K. & Lane, D. P. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat. Rev. Clin. Oncol. 15, 13\u201330 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10589_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Comprehensive genomic characterization","year":"2008","unstructured":"Comprehensive genomic characterization. Defines human glioblastoma genes and core pathways. Nature 455, 1061\u20131068 (2008).","journal-title":"Nature"},{"key":"10589_CR11","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1126\/science.8266084","volume":"262","author":"DE Koshland","year":"1993","unstructured":"Koshland, D. E. Molecule of the year. Sci. (80-). 262, 1953\u20131953 (1993).","journal-title":"Sci. (80-)"},{"key":"10589_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-022-01314-3","volume":"15","author":"H Zhu","year":"2022","unstructured":"Zhu, H. et al. Targeting p53\u2013MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials. J. Hematol. Oncol. 15, 91 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"10589_CR13","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/leu.2016.350","volume":"31","author":"A Quint\u00e1s-Cardama","year":"2017","unstructured":"Quint\u00e1s-Cardama, A. et al. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia 31, 1296\u20131305 (2017).","journal-title":"Leukemia"},{"key":"10589_CR14","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/nar\/26.15.3453","volume":"26","author":"J Momand","year":"1998","unstructured":"Momand, J. The MDM2 gene amplification database. Nucleic Acids Res. 26, 3453\u20133459 (1998).","journal-title":"Nucleic Acids Res."},{"key":"10589_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","volume":"49","author":"S Shangary","year":"2009","unstructured":"Shangary, S. & Wang, S. Small-Molecule inhibitors of the MDM2-p53 Protein-Protein interaction to reactivate p53 function: A novel approach for Cancer therapy. Annu. Rev. Pharmacol. Toxicol. 49, 223\u2013241 (2009).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10589_CR16","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.2174\/1381612811319180009","volume":"19","author":"T DeVine","year":"2013","unstructured":"DeVine, T. & Dai, M. S. Targeting the Ubiquitin-Mediated proteasome degradation of p53 for Cancer therapy. Curr. Pharm. Des. 19, 3248\u20133262 (2013).","journal-title":"Curr. Pharm. Des."},{"key":"10589_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ddstr.2011.10.002","volume":"8","author":"TI Oprea","year":"2011","unstructured":"Oprea, T. I. et al. Drug repurposing from an academic perspective. Drug Discov Today Ther. Strateg. 8, 61\u201369 (2011).","journal-title":"Drug Discov Today Ther. Strateg"},{"key":"10589_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","volume":"27","author":"K Park","year":"2019","unstructured":"Park, K. A review of computational drug repurposing. Transl Clin. Pharmacol. 27, 59 (2019).","journal-title":"Transl Clin. Pharmacol."},{"key":"10589_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov"},{"key":"10589_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3390\/cancers13040861","volume":"13","author":"B Alburquerque-Gonz\u00e1lez","year":"2021","unstructured":"Alburquerque-Gonz\u00e1lez, B. et al. The FDA-Approved antiviral raltegravir inhibits Fascin1-Dependent invasion of colorectal tumor cells in vitro and in vivo. Cancers (Basel). 13, 861 (2021).","journal-title":"Cancers (Basel)"},{"key":"10589_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/187152011795347513","volume":"11","author":"J Garcia-Quiroz","year":"2011","unstructured":"Garcia-Quiroz, J. & Camacho, J. Astemizole: an old Anti-histamine as a new promising Anti-cancer drug. Anticancer Agents Med. Chem. 11, 307\u2013314 (2011).","journal-title":"Anticancer Agents Med. Chem."},{"key":"10589_CR22","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-15-0461","volume":"21","author":"Y Guo","year":"2015","unstructured":"Guo, Y. et al. A novel Pharmacologic activity of ketorolac for therapeutic benefit in ovarian Cancer patients. Clin. Cancer Res. 21, 5064\u20135072 (2015).","journal-title":"Clin. Cancer Res."},{"key":"10589_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/antibiotics12010137","volume":"12","author":"B R\u00e1cz","year":"2023","unstructured":"R\u00e1cz, B. & Spengler, G. Repurposing antidepressants and phenothiazine antipsychotics as efflux pump inhibitors in Cancer and infectious diseases. Antibiotics 12, 137 (2023).","journal-title":"Antibiotics"},{"key":"10589_CR24","doi-asserted-by":"publisher","unstructured":"Tiwari, A. & Singh, S. Computational approaches in drug designing. in Bioinformatics 207\u2013217Elsevier, (2022). https:\/\/doi.org\/10.1016\/B978-0-323-89775-4.00010-9","DOI":"10.1016\/B978-0-323-89775-4.00010-9"},{"key":"10589_CR25","doi-asserted-by":"publisher","unstructured":"Yu, W. & MacKerell, A. D. Computer-Aided drug design methods. in 85\u2013106 (2017). https:\/\/doi.org\/10.1007\/978-1-4939-6634-9_5","DOI":"10.1007\/978-1-4939-6634-9_5"},{"key":"10589_CR26","doi-asserted-by":"publisher","first-page":"504","DOI":"10.22270\/jddt.v8i5.1894","volume":"8","author":"S Surabhi","year":"2018","unstructured":"Surabhi, S., Singh, B. & COMPUTER AIDED DRUG DESIGN: AN OVERVIEW. J. Drug Deliv Ther. 8, 504\u2013509 (2018).","journal-title":"J. Drug Deliv Ther."},{"key":"10589_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/1568005033342145","volume":"3","author":"A Veselovsky","year":"2003","unstructured":"Veselovsky, A. & Ivanov, A. Strategy of Computer-Aided drug design. Curr. Drug Target. -Infectious Disord. 3, 33\u201340 (2003).","journal-title":"Curr. Drug Target. -Infectious Disord"},{"key":"10589_CR28","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2174\/1381612822666151125000550","volume":"22","author":"M Hassan Baig","year":"2016","unstructured":"Hassan Baig, M. et al. Computer aided drug design: success and limitations. Curr. Pharm. Des. 22, 572\u2013581 (2016).","journal-title":"Curr. Pharm. Des."},{"key":"10589_CR29","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1016\/j.bmcl.2018.08.027","volume":"28","author":"A Vaupel","year":"2018","unstructured":"Vaupel, A. et al. In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor. Bioorg. Med. Chem. Lett. 28, 3404\u20133408 (2018).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10589_CR30","doi-asserted-by":"publisher","unstructured":"In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor. at (2018). https:\/\/doi.org\/10.2210\/pdb6ggn\/pdb","DOI":"10.2210\/pdb6ggn\/pdb"},{"key":"10589_CR31","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1080\/07391102.2021.2024449","volume":"41","author":"S Yadav","year":"2023","unstructured":"Yadav, S., Ahamad, S., Gupta, D. & Mathur, P. Lead optimization, pharmacophore development and scaffold design of protein kinase CK2 inhibitors as potential COVID-19 therapeutics. J. Biomol. Struct. Dyn. 41, 1811\u20131827 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10589_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"G Madhavi Sastry","year":"2013","unstructured":"Madhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221\u2013234 (2013).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10589_CR33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","volume":"21","author":"JC Shelley","year":"2007","unstructured":"Shelley, J. C. et al. Epik: a software program for pK a prediction and protonation state generation for drug-like molecules. J. Comput. Aided Mol. Des. 21, 681\u2013691 (2007).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10589_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33435\/tcandtc.1224592","volume":"8","author":"Y Hasan","year":"2024","unstructured":"Hasan, Y. & Al-hamashi, A. Identification of Selisistat derivatives as SIRT1-3 inhibitors by in Silico virtual screening. Turkish Comput. Theor. Chem. 8, 1\u201311 (2024).","journal-title":"Turkish Comput. Theor. Chem."},{"key":"10589_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1021\/ci800324m","volume":"49","author":"TA Halgren","year":"2009","unstructured":"Halgren, T. A. Identifying and characterizing binding sites and assessing druggability. J. Chem. Inf. Model. 49, 377\u2013389 (2009).","journal-title":"J. Chem. Inf. Model."},{"key":"10589_CR36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.sjbs.2020.10.023","volume":"28","author":"JJ Sahayarayan","year":"2021","unstructured":"Sahayarayan, J. J. et al. In-silico protein-ligand Docking studies against the Estrogen protein of breast cancer using pharmacophore based virtual screening approaches. Saudi J. Biol. Sci. 28, 400\u2013407 (2021).","journal-title":"Saudi J. Biol. Sci."},{"key":"10589_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1039\/b209064n","volume":"34","author":"JJ Perez","year":"2005","unstructured":"Perez, J. J. Managing molecular diversity. Chem. Soc. Rev. 34, 143 (2005).","journal-title":"Chem. Soc. Rev."},{"key":"10589_CR38","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1021\/ci100026x","volume":"50","author":"IJ Chen","year":"2010","unstructured":"Chen, I. J. & Foloppe, N. Drug-like bioactive structures and conformational coverage with the ligprep\/confgen suite: comparison to programs MOE and catalyst. J. Chem. Inf. Model. 50, 822\u2013839 (2010).","journal-title":"J. Chem. Inf. Model."},{"key":"10589_CR39","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1021\/acs.jctc.8b01026","volume":"15","author":"K Roos","year":"2019","unstructured":"Roos, K. et al. OPLS3e: extending force field coverage for Drug-Like small molecules. J. Chem. Theory Comput. 15, 1863\u20131874 (2019).","journal-title":"J. Chem. Theory Comput."},{"key":"10589_CR40","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","volume":"17","author":"C Lu","year":"2021","unstructured":"Lu, C. et al. OPLS4: improving force field accuracy on challenging regimes of chemical space. J. Chem. Theory Comput. 17, 4291\u20134300 (2021).","journal-title":"J. Chem. Theory Comput."},{"key":"10589_CR41","doi-asserted-by":"publisher","unstructured":"Schaller, D. et al. Next generation 3D pharmacophore modeling. WIREs Comput. Mol. Sci 10, e1468. https:\/\/doi.org\/10.1002\/wcms.1468 (2020).","DOI":"10.1002\/wcms.1468"},{"key":"10589_CR42","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1021\/ci900212v","volume":"49","author":"NK Salam","year":"2009","unstructured":"Salam, N. K., Nuti, R. & Sherman, W. Novel method for generating Structure-Based pharmacophores using energetic analysis. J. Chem. Inf. Model. 49, 2356\u20132368 (2009).","journal-title":"J. Chem. Inf. Model."},{"key":"10589_CR43","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10822-006-9087-6","volume":"20","author":"SL Dixon","year":"2006","unstructured":"Dixon, S. L. et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des. 20, 647\u2013671 (2006).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10589_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3797\/scipharm.0803-03","volume":"76","author":"V Vyas","year":"2008","unstructured":"Vyas, V. & Virtual Screening A fast tool for drug design. Sci. Pharm. 76, 333\u2013360 (2008).","journal-title":"Sci. Pharm."},{"key":"10589_CR45","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/aps.2009.159","volume":"30","author":"Z Chen","year":"2009","unstructured":"Chen, Z. et al. Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets. Acta Pharmacol. Sin. 30, 1694\u20131708 (2009).","journal-title":"Acta Pharmacol. Sin"},{"key":"10589_CR46","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/jm030644s","volume":"47","author":"TA Halgren","year":"2004","unstructured":"Halgren, T. A. et al. Glide: A new approach for rapid, accurate Docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750\u20131759 (2004).","journal-title":"J. Med. Chem."},{"key":"10589_CR47","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.1080\/07391102.2022.2141895","volume":"41","author":"B Sharma","year":"2023","unstructured":"Sharma, B., Bhattacherjee, D., Zyryanov, G. V. & Purohit, R. An insight from computational approach to explore novel, high-affinity phosphodiesterase 10A inhibitors for neurological disorders. J. Biomol. Struct. Dyn. 41, 9424\u20139436 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10589_CR48","doi-asserted-by":"publisher","first-page":"151614","DOI":"10.1016\/j.bbrc.2025.151614","volume":"758","author":"B Sharma","year":"2025","unstructured":"Sharma, B. & Purohit, R. Enhanced sampling simulations to explore Himalayan phytochemicals as potential phosphodiesterase-1 inhibitor for neurological disorders. Biochem. Biophys. Res. Commun. 758, 151614 (2025).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10589_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10822-007-9165-4","volume":"22","author":"IJ Enyedy","year":"2008","unstructured":"Enyedy, I. J. & Egan, W. J. Can we use Docking and scoring for hit-to-lead optimization? J. Comput. Aided Mol. Des. 22, 161\u2013168 (2008).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10589_CR50","doi-asserted-by":"publisher","unstructured":"Chukwuemeka, P. O. et al. Targeting dysregulation signatures of p53-MDM2 interactions to identify newer small molecule inhibitors for cancer therapy: Insight from computational direction. at (2021). https:\/\/doi.org\/10.21203\/rs.3.rs-217761\/v1","DOI":"10.21203\/rs.3.rs-217761\/v1"},{"key":"10589_CR51","doi-asserted-by":"publisher","first-page":"173664","DOI":"10.1016\/j.ejphar.2020.173664","volume":"890","author":"S Ahamad","year":"2021","unstructured":"Ahamad, S., Kanipakam, H., Birla, S., Ali, M. S. & Gupta, D. Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 mpro, using molecular Docking and dynamics simulation studies. Eur. J. Pharmacol. 890, 173664 (2021).","journal-title":"Eur. J. Pharmacol."},{"key":"10589_CR52","doi-asserted-by":"publisher","unstructured":"Haider, K. et al. Design, synthesis, biological evaluation, and in Silico studies of 2-aminobenzothiazole derivatives as potent PI3K\u03b1 inhibitors. Arch Pharm. (Weinheim) 355 (10), 2200146. https:\/\/doi.org\/10.1002\/ardp.202200146 (2022).","DOI":"10.1002\/ardp.202200146"},{"key":"10589_CR53","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/qsar.200730051","volume":"27","author":"L Ioakimidis","year":"2008","unstructured":"Ioakimidis, L., Thoukydidis, L., Mirza, A., Naeem, S. & Reynisson, J. Benchmarking the reliability of qikprop. Correlation between experimental and predicted values. QSAR Comb. Sci. 27, 445\u2013456 (2008).","journal-title":"QSAR Comb. Sci."},{"key":"10589_CR54","doi-asserted-by":"publisher","unstructured":"Perkin, V. O., Antonyan, G. V., Radchenko, E. V. & Palyulin, V. A. Web services for the prediction of ADMET parameters relevant to the design of neuroprotective drugs. in 465\u2013485 (2023). https:\/\/doi.org\/10.1007\/978-1-0716-3311-3_16","DOI":"10.1007\/978-1-0716-3311-3_16"},{"key":"10589_CR55","doi-asserted-by":"publisher","first-page":"107105","DOI":"10.1016\/j.compbiolchem.2019.107105","volume":"83","author":"H Sirous","year":"2019","unstructured":"Sirous, H., Chemi, G., Campiani, G. & Brogi, S. An integrated in Silico screening strategy for identifying promising disruptors of p53-MDM2 interaction. Comput. Biol. Chem. 83, 107105 (2019).","journal-title":"Comput. Biol. Chem."},{"key":"10589_CR56","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/prot.22890","volume":"79","author":"JM Hayes","year":"2011","unstructured":"Hayes, J. M. et al. Kinetics, in Silico docking, molecular dynamics, and MM-GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP\u2010binding site inhibitors: the role of water molecules examined. Proteins Struct. Funct. Bioinforma. 79, 703\u2013719 (2011).","journal-title":"Proteins Struct. Funct. Bioinforma"},{"key":"10589_CR57","doi-asserted-by":"publisher","first-page":"129311","DOI":"10.1016\/j.molstruc.2020.129311","volume":"1223","author":"JA Abdullah","year":"2021","unstructured":"Abdullah, J. A. et al. Synthesis, characterization and in-silico assessment of novel Thiazolidinone derivatives for cyclin-dependent kinases-2 inhibitors. J. Mol. Struct. 1223, 129311 (2021).","journal-title":"J. Mol. Struct."},{"key":"10589_CR58","doi-asserted-by":"publisher","unstructured":"Bowers, K. J. et al. Molecular dynamics\u2014Scalable algorithms for molecular dynamics simulations on commodity clusters. in Proceedings of the ACM\/IEEE conference on Supercomputing - SC \u201906 84 (ACM Press, New York, New York, USA, 2006). 84 (ACM Press, New York, New York, USA, 2006). (2006). https:\/\/doi.org\/10.1145\/1188455.1188544","DOI":"10.1145\/1188455.1188544"},{"key":"10589_CR59","doi-asserted-by":"crossref","unstructured":"P., G. & M. K., K.\u00a0Docking studies and molecular dynamics simulation of Triazole benzene sulfonamide derivatives with human carbonic anhydrase IX Inhibition activity. RSC Adv. 11, 38079\u201338093 (2021).","DOI":"10.1039\/D1RA07377J"},{"key":"10589_CR60","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/00268976.2010.513345","volume":"109","author":"C Huang","year":"2011","unstructured":"Huang, C., Li, C., Choi, P. Y. K., Nandakumar, K. & Kostiuk, L. W. A novel method for molecular dynamics simulation in the isothermal\u2013isobaric ensemble. Mol. Phys. 109, 191\u2013202 (2011).","journal-title":"Mol. Phys."},{"key":"10589_CR61","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.rser.2017.08.020","volume":"81","author":"CB Ong","year":"2018","unstructured":"Ong, C. B., Ng, L. Y. & Mohammad, A. W. A review of ZnO nanoparticles as solar photocatalysts: synthesis, mechanisms and applications. Renew. Sustain. Energy Rev. 81, 536\u2013551 (2018).","journal-title":"Renew. Sustain. Energy Rev."},{"key":"10589_CR62","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1080\/07391102.2018.1444510","volume":"37","author":"S Jana","year":"2019","unstructured":"Jana, S. & Singh, S. K. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches. J. Biomol. Struct. Dyn. 37, 944\u2013965 (2019).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10589_CR63","doi-asserted-by":"publisher","first-page":"127241","DOI":"10.1016\/j.molstruc.2019.127241","volume":"1202","author":"JI Ahamed","year":"2020","unstructured":"Ahamed, J. I. et al. A combined experimental and DFT computations study of novel (E)-3-(benzofuran-2-yl)-2-(thiophen-2-yl)acrylonitrile(TACNBNF): insight into the synthesis, single crystal XRD, NMR, vibrational spectral analysis, in vitro antioxidant and in Silico molecular d. J. Mol. Struct. 1202, 127241 (2020).","journal-title":"J. Mol. Struct."},{"key":"10589_CR64","doi-asserted-by":"publisher","first-page":"119443","DOI":"10.1016\/j.ica.2020.119443","volume":"505","author":"M Ismael","year":"2020","unstructured":"Ismael, M., Abdel-Mawgoud, A. M. M., Rabia, M. K. & Abdou, A. Design and synthesis of three Fe(III) mixed-ligand complexes: exploration of their biological and phenoxazinone synthase-like activities. Inorganica Chim. Acta. 505, 119443 (2020).","journal-title":"Inorganica Chim. Acta"},{"key":"10589_CR65","doi-asserted-by":"publisher","unstructured":"Ahmad, S. et al. Molecular dynamics simulation and docking studies reveal NF-\u03baB as a promising therapeutic drug target for COVID-19. at (2021). https:\/\/doi.org\/10.21203\/rs.3.rs-469785\/v2","DOI":"10.21203\/rs.3.rs-469785\/v2"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10589-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10589-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10589-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:02:42Z","timestamp":1760137362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10589-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10589"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-10589-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34687"}}